Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according to a study published in the Jan. 9 issue of the New England Journal of Medicine.

Yael C. Cohen, M.D., from the Tel Aviv Sourasky Medical Center in Israel, and colleagues conducted a phase 1b-2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. Five dose levels were investigated in a dose-escalation study in phase 1. The recommended phase 2 regimen was talquetamab at a dose of 0.8 mg/kg body weight plus teclistamab at a dose of 3.0 mg/kg every other week. The primary objective of the study was to evaluate adverse events and dose-limiting toxic effects.

Ninety-four patients received treatment; 44 used the recommended phase 2 regimen. Patients were followed for a median of 20.3 months. The researchers found that three patients had dose-limiting toxic effects (including one with grade 4 thrombocytopenia, who received the recommended phase 2 regimen). The most common adverse events across all dose levels were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Ninety-six percent of patients had grade 3 or 4 adverse events, most often hematologic events. Sixty-four percent of patients had grade 3 or 4 infections. A response occurred in 80 percent of the patients with the recommended phase 2 regimen and in 78 percent across all dose levels. The likelihood of patients continuing in response at 18 months was 86 and 77 percent with the recommended phase 2 regimen and across all dose levels, respectively.

"On the basis of these results, this dual-targeting, off-the-shelf combination therapy warrants further investigation in patients with relapsed or refractory multiple myeloma," the authors write.

The study was funded by Janssen, which manufactures talquetamab and teclistamab.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-10 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords